StockData

Pliant Therapeutics vs Zentalis Pharmaceuticals

PLRX and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PLRX and ZNTL compare

Zentalis Pharmaceuticals is the larger company, worth 2.6 times as much as Pliant Therapeutics ($107M against $40.9M).

Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 3 for Pliant Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPLRXZNTL
Size and price
Market cap$40.9M$107M
Share price$0.660$1.49
Change, 1 year−60.7%12.0%
Change, 5 years−95.4%−98.0%
Beta (5Y)0.955.80
Employees49106
StockData Score
Total score36 (better)
Valuation score11
Growth score00
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/B0.3× (better)0.7×
FCF yield−173%−120% (better)
Profitability
Return on equity−50.3% (better)−66.7%
Financial health
Debt / equity–0.00
Interest coverage−102.5×–
Current ratio9.90 (better)4.82
Altman Z-score−6.85 (better)−8.91
Piotroski F-score2 (better)1
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions77.7%66.1%
Held by insiders13.0%58.0%
Insider net buying, 12 months−$164K$12.8M (better)
Short interest, % of float9.1%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.